Skip to main content

We’re happy to announce Newswire has acquired HeadTalker!

From the beginning of HeadTalker, we have always placed the comments and happiness of our community first and we believe with this acquisition, we’ll continue to build out our vision for social media virality for brand campaigns as well as improving the opportunities to our user base.

Newswire and HeadTalker are committed to create new and better ways to take a social media message viral.

For now, HeadTalker with continue to function as it does today. Your Headtalker account and campaigns will continue as normal and we’ll be providing more details on upcoming plans for Headtalker in the coming weeks.

If you have any questions, please contact us.

Team HeadTalker and Newswire

Batu Biologics: ValloVax

By Samuel Wagner

Created 8 | Supported 2

27 of 25



Social Reach


Ended 04/14/2017

"Batu Biologics is developing a novel method of treating cancer by targeting the tumor blood vessels"

— Samuel Wagner and
other supporters

Share | How It Works | Embed

Batu Biologics is a biotechnology-based pharmaceutical company focused on the development and commercialization of novel therapies that target the “Achilles Heel of Cancer”: the tumor blood vessels. Our lead product is a  therapeutic vaccine targeting the tumor endothelium, ValloVax™.   We are preparing to initiate a Phase I study for advanced lung cancer with the US FDA and are looking to expand awareness to our program. Please share this message and view our website to learn more about our vision for the future of cancer immunotherapy.  

No Campaign Updates. Check Back Sometime Soon.

Created on 2023-04-13 17:53:18